| Core Laboratories Down 30% YTD: Should You Hold or Sell the Stock? |
CLB struggles with a 4.4% revenue decline, low ROIC in the first quarter of 2025, minimal dividends and vulnerability to oil price volatility and geopolitical instability. |
zacks.com |
2025-05-15 14:36:07 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for May 14th |
AMTB, CLB and EXPI have been added to the Zacks Rank #5 (Strong Sell) List on May 14, 2025. |
zacks.com |
2025-05-14 11:35:36 |
Czytaj oryginał (ang.) |
| Core Laboratories Q1 Earnings Miss Estimates, Expenses Increase YoY |
CLB's first-quarter earnings miss estimates due to the underperformance of the Reservoir Description segment. |
zacks.com |
2025-04-25 12:00:41 |
Czytaj oryginał (ang.) |
| Core Laboratories Inc. (CLB) Q1 2025 Earnings Call Transcript |
Core Laboratories Inc. (NYSE:CLB ) Q1 2025 Earnings Conference Call April 24, 2025 8:30 AM ET Company Participants Larry Bruno - Chairman and Chief Executive Officer Gwen Gresham - Senior Vice President and Head, Investor Relations Chris Hill - Chief Financial Officer Conference Call Participants Stephen Gengaro - Stifel Sean Mitchell - Daniel Energy Partners Operator Good day, and welcome to the Core Laboratories First Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded. |
seekingalpha.com |
2025-04-24 18:14:51 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for April 24th |
AMPY, CARS and CLB have been added to the Zacks Rank #5 (Strong Sell) List on April 24, 2025. |
zacks.com |
2025-04-24 11:25:29 |
Czytaj oryginał (ang.) |
| Core Laboratories (CLB) Q1 Earnings and Revenues Lag Estimates |
Core Laboratories (CLB) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.19 per share a year ago. |
zacks.com |
2025-04-23 23:10:36 |
Czytaj oryginał (ang.) |
| CORE LAB REPORTS FIRST QUARTER 2025 RESULTS |
REVENUE OF $123.6 MILLION, DOWN 4% SEQUENTIALLY AND 5% YEAR-OVER-YEAR OPERATING INCOME OF $4.4 MILLION; EX-ITEMS, $11.8 MILLION, DOWN 25% SEQUENTIALLY AND 21% YEAR-OVER-YEAR OPERATING MARGINS, EX-ITEMS, OF 10% GAAP EPS OF $0.00; EX-ITEMS, $0.14, DOWN 35% SEQUENTIALLY, AND 25% YEAR-OVER-YEAR FREE CASH FLOW OF $3.9 MILLION, UP OVER 50% YEAR-OVER-YEAR NET DEBT REDUCED BY $4.9 MILLION; DEBT LEVERAGE RATIO REMAINS AT 1.31 COMPANY REPURCHASED 131,598 SHARES OF COMMON STOCK, A VALUE OF $2.0 MILLION COMPANY ANNOUNCES Q1 2025 QUARTERLY DIVIDEND HOUSTON , April 23, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported first quarter 2025 revenue of $123,600,000. Core's operating income was $4,400,000, with earnings per diluted share ("EPS") of $0.00, all in accordance with U.S. generally accepted accounting principles ("GAAP"). |
prnewswire.com |
2025-04-23 21:15:00 |
Czytaj oryginał (ang.) |
| Core Laboratories to Post Q1 Earnings: Key Metrics to Watch |
CLB's first-quarter revenues are likely to have declined from the year-ago period's level. However, cost reductions are expected to have provided modest relief. |
zacks.com |
2025-04-21 10:40:34 |
Czytaj oryginał (ang.) |
| Earnings Preview: Core Laboratories (CLB) Q1 Earnings Expected to Decline |
Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-16 15:07:01 |
Czytaj oryginał (ang.) |
| Here's How to Play Core Labs Stock Ahead of Its Q1 Earnings Release |
CLB faces declining revenues, weak margins, geopolitical disruptions and inventory issues, with low dividend yield and overvaluation increasing investor caution. |
zacks.com |
2025-04-14 11:20:45 |
Czytaj oryginał (ang.) |
| CORE LABORATORIES ANNOUNCES TIMING OF FIRST QUARTER 2025 EARNINGS RELEASE AND CONFERENCE CALL |
HOUSTON, March 24, 2025 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its first quarter 2025 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m. EST on April 24, 2025. |
prnewswire.com |
2025-03-24 18:15:00 |
Czytaj oryginał (ang.) |
| Is Core Stock Worth Buying After a 27% Surge in 6 Months? |
CLB stock is supported by international expansion, proprietary tech and solid cash flow amid competitive pricing, volatile oil prices and geopolitical tensions. |
zacks.com |
2025-03-03 09:20:36 |
Czytaj oryginał (ang.) |
| Why Is Core Laboratories (CLB) Down 16% Since Last Earnings Report? |
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2025-02-28 14:36:13 |
Czytaj oryginał (ang.) |
| CLB's Q4 Earnings Beat Estimates, Sales Lag, Expenses Increase |
Core Laboratories expects Reservoir Description revenues of $82-$85 million and Production Enhancement revenues of $39-$42 million for the first quarter of 2025. |
zacks.com |
2025-01-31 09:57:11 |
Czytaj oryginał (ang.) |
| Core Laboratories Inc. (CLB) Q4 2024 Earnings Conference Call Transcript |
Core Laboratories Inc. (NYSE:CLB ) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Larry Bruno - Chairman and Chief Executive Officer Gwen Gresham - Senior Vice President and Head, Investor Relations Chris Hill - Chief Financial Officer Conference Call Participants Stephen Gengaro - Stifel Josh Jayne - Daniel Energy Partners David Smith - Pickering Energy Partners Operator Good day, and welcome to the Core Laboratories' Fourth Quarter 2024 Earnings Call. All participants will be in listen-only mode. |
seekingalpha.com |
2025-01-31 00:05:15 |
Czytaj oryginał (ang.) |
| Core Laboratories (CLB) Misses Q4 Earnings and Revenue Estimates |
Core Laboratories (CLB) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.19 per share a year ago. |
zacks.com |
2025-01-29 21:31:13 |
Czytaj oryginał (ang.) |
| CORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS |
FOURTH QUARTER REVENUE OF $129.2 MILLION, DOWN 4% SEQUENTIALLY AND UP SLIGHTLY YEAR-OVER-YEAR FOURTH QUARTER OPERATING INCOME OF $14.2 MILLION; EX-ITEMS, $15.7 MILLION, DOWN 14% SEQUENTIALLY, UP 4% YEAR-OVER-YEAR FOURTH QUARTER OPERATING MARGINS, EX-ITEMS, OF 12% FOURTH QUARTER GAAP EPS OF $0.15; EX-ITEMS, $0.22, DOWN 12% SEQUENTIALLY, UP 16% YEAR-OVER-YEAR FOURTH QUARTER FREE CASH FLOW OF $16.2 MILLION, UP OVER 50% SEQUENTIALLY DEBT LEVERAGE RATIO REDUCED TO 1.31, AND NET DEBT REDUCED BY $11.7 MILLION COMPANY REPURCHASED 264,982 SHARES OF COMMON STOCK, A VALUE OF $4.9 MILLION, DURING THE FOURTH QUARTER COMPANY ANNOUNCES Q1 2025 QUARTERLY DIVIDEND FULL YEAR REVENUE OF $523.8 MILLION, UP 3% FULL YEAR OPERATING INCOME OF $58.6 MILLION; EX-ITEMS, $65.3 MILLION, UP 7% FULL YEAR GAAP EPS OF $0.66; EX-ITEMS, EPS OF $0.87, UP 9% FULL YEAR FREE CASH FLOW OF $43.4 MILLION, UP OVER 200% COMPARED TO 2023 HOUSTON , Jan. 29, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported fourth quarter 2024 revenue of $129,200,000. Core's operating income was $14,200,000, with diluted earnings per share ("EPS") of $0.15, all in accordance with U.S. generally accepted accounting principles ("GAAP"). |
prnewswire.com |
2025-01-29 19:15:00 |
Czytaj oryginał (ang.) |
| Core Laboratories to Post Q4 Earnings: Here's What to Expect |
CLB is expected to report higher revenues from the year-ago period's level. However, despite this revenue growth, the company is expected to face increased operating expenses. |
zacks.com |
2025-01-24 09:15:42 |
Czytaj oryginał (ang.) |
| Core Laboratories (CLB) Reports Next Week: Wall Street Expects Earnings Growth |
Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-01-22 13:06:55 |
Czytaj oryginał (ang.) |
| Here's Why Hold Strategy is Apt for Core Laboratories Stock Now |
CLB benefits from strong international growth, high-margin projects and an efficient business model. However, stock underperformance, competition and U.S. market challenges pose risks. |
zacks.com |
2025-01-15 09:05:35 |
Czytaj oryginał (ang.) |
| Clinical Chemistry and Immunoassay Industry Forecast Report to 2028: Integrated and Scalable Core Lab Solutions Driving Transformational Growth |
Dublin, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The "Clinical Chemistry and Immunoassay Industry, Global, 2023-2028" report has been added to ResearchAndMarkets.com's offering. This analysis examines the global clinical chemistry and immunoassay sector, accounting for the highest share in the in vitro diagnostics (IVD) market. This type of lab-based testing analyzes body fluids (usually blood, urine, or saliva) using integrated/standalone analyzers and a wide range of assays/panels, among other solutions and services to support the diagnosis and treatment of human health. While clinical chemistry instruments and tests target different chemicals in body fluids to evaluate health and the clinical management of patients, immunoassay instruments and tests measure the presence or concentration of analytes in biological liquid by using the binding of antibodies to antigens to identify and measure certain substances. This competitive analysis examines IVD companies that provide a broad menu of clinical chemistry and immunoassay systems, including instruments and consumables. |
globenewswire.com |
2024-12-17 16:20:00 |
Czytaj oryginał (ang.) |
| Is Now the Right Time to Buy Core Laboratories After Its 12% YTD Rise? |
CLB shows strong earnings growth, solid cash flow and innovative technologies, but faces risks from geopolitical tensions, weak U.S. onshore activity and oil price volatility. |
zacks.com |
2024-12-13 09:51:17 |
Czytaj oryginał (ang.) |
| Why Is Core Laboratories (CLB) Up 11.5% Since Last Earnings Report? |
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-11-22 14:37:12 |
Czytaj oryginał (ang.) |
| Is the Options Market Predicting a Spike in CORE LABS INC (CLB) Stock? |
Investors need to pay close attention to CORE LABS INC (CLB) stock based on the movements in the options market lately. |
zacks.com |
2024-11-07 12:16:24 |
Czytaj oryginał (ang.) |
| Core Laboratories Inc. (CLB) Q3 2024 Earnings Call Transcript |
Core Laboratories Inc. (NYSE:CLB ) Q3 2024 Earnings Conference Call October 24, 2024 8:30 AM ET Company Participants Larry Bruno - Chairman and Chief Executive Officer Chris Hill - Chief Financial Officer Gwen Gresham - Senior Vice President and Head, Investor Relations Conference Call Participants Sean Mitchell - Daniel Energy Partners Stephen Gengaro - Stifel Operator Good day and welcome to the Core Lab Q3 2024 Earnings Conference Call. All participants will be in a listen-only mode. |
seekingalpha.com |
2024-10-24 16:53:05 |
Czytaj oryginał (ang.) |
| Core Laboratories' Q3 Earnings and Sales Beat Estimates |
CLB expects Reservoir Description revenues of $87.5-$90.5 million and Production Enhancement revenues of $41-$45 million for the fourth quarter of 2024. |
zacks.com |
2024-10-24 11:41:09 |
Czytaj oryginał (ang.) |
| Core Laboratories (CLB) Q3 Earnings Match Estimates |
Core Laboratories (CLB) came out with quarterly earnings of $0.25 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.22 per share a year ago. |
zacks.com |
2024-10-23 23:25:19 |
Czytaj oryginał (ang.) |
| CORE LAB REPORTS THIRD QUARTER 2024 RESULTS |
THIRD QUARTER REVENUE OF $134.4 MILLION, UP 3% SEQUENTIALLY AND OVER 7% YEAR-OVER-YEAR THIRD QUARTER OPERATING INCOME OF $19.8 MILLION; EX-ITEMS, $18.2 MILLION, UP 11% SEQUENTIALLY AND 14% YEAR-OVER-YEAR THIRD QUARTER OPERATING MARGINS, EX-ITEMS, OF 14% UP 100 BPS SEQUENTIALLY THIRD QUARTER GAAP EPS OF $0.25; EX-ITEMS, $0.25, UP 14% SEQUENTIALLY AND YEAR-OVER-YEAR THIRD QUARTER FREE CASH FLOW OF $10.4 MILLION NET DEBT REDUCED BY $11.8 MILLION; DEBT LEVERAGE RATIO REDUCED TO 1.47 COMPANY ANNOUNCES Q4 2024 QUARTERLY DIVIDEND HOUSTON , Oct. 23, 2024 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported third quarter 2024 revenue of $134,400,000. Core's operating income was $19,800,000, with diluted earnings per share ("EPS") of $0.25, all in accordance with U.S. generally accepted accounting principles ("GAAP"). |
prnewswire.com |
2024-10-23 21:15:00 |
Czytaj oryginał (ang.) |
| Energy Stocks to Watch Amid Q3 Earnings Despite Pricing Pressures |
Energy stocks such as PUMP, CLB and OII are poised to deliver a Q3 earnings beat. |
zacks.com |
2024-10-22 16:00:21 |
Czytaj oryginał (ang.) |
| What's in Store for Core Laboratories Stock in Q3 Earnings? |
CLB is expected to report higher revenues compared with the previous quarter, along with reduced costs for services and product sales and general administrative expenses. |
zacks.com |
2024-10-17 12:55:20 |
Czytaj oryginał (ang.) |
| Can Core Laboratories (CLB) Keep the Earnings Surprise Streak Alive? |
Core Laboratories (CLB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2024-10-16 17:15:28 |
Czytaj oryginał (ang.) |
| Core Laboratories (CLB) Earnings Expected to Grow: What to Know Ahead of Next Week's Release |
Core Laboratories (CLB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-16 15:06:08 |
Czytaj oryginał (ang.) |
| Here's Why Core Laboratories (CLB) is a Strong Value Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-10-15 14:46:20 |
Czytaj oryginał (ang.) |
| Equinor Strengthens Offshore Wind Portfolio With 9.8% Stake in Orsted |
EQNR secures a 9.8% stake in Orsted, becoming the latter's second-largest shareholder and advancing its commitment to offshore wind and renewable energy growth. |
zacks.com |
2024-10-08 15:30:24 |
Czytaj oryginał (ang.) |
| 3 Energy Stocks to Buy on Continued Geopolitical Turmoil |
Buy energy stocks like Sasol (SSL), Core Lab (CLB) and Nine Energy (NINE) for steady returns in a volatile macroeconomic environment. |
zacks.com |
2024-10-08 13:20:14 |
Czytaj oryginał (ang.) |
| Is Now the Right Time to Buy Core Laboratories After Its 14% YTD Rise? |
CLB is a compelling investment in the oilfield services sector, featuring strong fundamentals, innovative technologies and a disciplined financial strategy poised for growth. |
zacks.com |
2024-10-08 12:48:25 |
Czytaj oryginał (ang.) |
| Eni-Ithaca Merger Expands Footprint in North Sea Oil and Gas |
E's upstream merger with Ithaca Energy creates a major player in the North Sea, setting the stage for substantial oil and gas production and UK energy security. |
zacks.com |
2024-10-04 14:10:39 |
Czytaj oryginał (ang.) |
| OPEC's Forecast of Peak Oil Demand: A Long Horizon Ahead |
Considering OPEC's optimistic oil demand growth forecast, we recommend buying stocks like CLB, FTI and TUWOY. |
zacks.com |
2024-09-26 20:01:12 |
Czytaj oryginał (ang.) |
| Are Oils-Energy Stocks Lagging CORE LABS INC (CLB) This Year? |
Here is how Core Laboratories (CLB) and Talen Energy Corporation (TLN) have performed compared to their sector so far this year. |
zacks.com |
2024-09-19 14:46:19 |
Czytaj oryginał (ang.) |
| Core Laboratories (CLB) Loses -10.14% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
The heavy selling pressure might have exhausted for Core Laboratories (CLB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2024-09-04 14:37:02 |
Czytaj oryginał (ang.) |